News
Ensuring Safe Vaccine Drug Substance Storage and Shipping
Responding to the emerging challenge of rapid vaccine production and global distribution is at the forefront to ending the global COVID-19 pandemic.
With various vaccine candidates currently in clinical trials, manufacturers are scaling-up their single-use production facilities to address the...
News
uMotif evolves leadership team with appointment of Steve Rosenberg as CEO
uMotif, a leading eClinical platform provider powering patient-centric research, announced a reorganisation of its leadership structure as Steve Rosenberg is appointed CEO. The announcement forms part of a wider evolution of uMotif’s executive team, with Julia Lakeland also joining...
News
Saphnelo approved in Japan for systemic lupus erythematosus
AstraZeneca’s Saphnelo (anifrolumab) has been approved in Japan for the treatment of adult patients with systemic lupus erythematosus (SLE), a serious autoimmune disease, who show insufficient response to currently available treatment.
The approval by the Japanese Ministry of Health, Labour...
Drug Research
Sanofi to focus its COVID-19 development efforts on the recombinant vaccine candidate
Recent positive interim results of Sanofi’s mRNA-based COVID-19 vaccine candidate Phase 1/2 study confirm the company’s platform robust capabilities and strategy in mRNA.
Taking into account public health needs and given sufficient mRNA COVID-19 vaccines supply can be expected going...
Drug Research
Syndax and Incyte Announce Global Collaboration to Develop and Commercialize Axatilimab for Chronic Graft-Versus-Host Disease and Other Fibrotic Diseases
Syndax Pharmaceuticals, Inc. and Incyte announced that they have entered into an exclusive worldwide collaboration and license agreement to develop and commercialize axatilimab, Syndax’s anti-CSF-1R monoclonal antibody.
“This partnership has the potential to significantly expand and maximize the axatilimab program...
Drug Research
Union therapeutics signs deal with Innovent to develop orismilast in China
Union therapeutics has signed a strategic partnership and license agreement with Innovent Biologics to develop and commercialise its therapy, orismilast, in China.
A potent and selective next-generation PDE4 inhibitor for inflammatory dermatology conditions, orismilast possesses extensive anti-inflammatory properties.
Developed originally by...
News
Paradigm4 launches flexFS for high throughput and resource efficient management for life science and healthcare data in the cloud
Paradigm4, an integrated scientific data analytics company, has launched flexFS TM , its innovative, elastic cloud file system for flexible and more resource efficient data storage and scalable computing.
flexFS increases data agility and reduces the costs of working with...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
















